I have been thinking lately about issues related to the direction of research funding for the field of molecular imaging. I have to confess my preference for nuclear techniques in this regard since tracer techniques usually have the advantage of not perturbing the observed state. 

An exclusive interview with Michael Graham, MD, PhD, covering the latest developments in PET radiopharmaceuticals, from drugs just approved and blazing trail in clinical use, to compounds in the far reaches of research.

Continued shutdowns at research reactors throughout the world have created shortfalls in essential medical isotope supply for several years. 

The drive for heterogeneity in molecular imaging calls for management of complex imaging data in massive volumes, a task that is challenging information technology experts and medical community members alike. 

Molecular imaging has become increasingly important in the non-invasive diagnosis and monitoring of pediatric disease, whether known or suspected. Innovations in molecular oncology, neuroimaging and hybrid imaging are shaping how clinicians approach a range of diseases in children and young adults.

Pairing current reconstructed 2D images and digital breast tomosynthesis (DBT) is comparable to combining standard full-field digital mammography (FFDM) and DBT, according to research published in the June issue of Radiology.

Shakespeare called King Richard III a hunchback, but new genetic and reconstructive CT data show this story had more of a twist. Until recently, the exact nature and whereabouts of Richard's physical deformity was a mystery. While questions still daunt researchers, a compelling picture of the monarch's spine has emerged.

The use of PET radiopharmaceuticals increased from 17 percent to 26 percent in diagnostic nuclear medicine procedures, according to a report evaluating adverse effects published May 29 in the Journal of Nuclear Medicine.